The phase II randomized ATOMICC trial (NCT03833479) [57] was designed to evaluate the role of the anti-PD1 dostarlimab as maintenance therapy in high-risk locally advanced cervical cancer (FIGO 2009 stages IB2, IIA2, and IIB with at least two positive pelvic nodes; stages IIIA, IIIB, IVA; or any stage with at least one positive para-aortic lymph node) who achieved a partial or complete response after CCRT. This evidence concerns the gene PDCD1 and cervical carcinoma.